USSTOCK.TODAY
Market Closed
Log in Sign up

UBS assigns buy rating to Viking Therapeutics, sets price target at $94

The Motley Fool +1 · ·by G4L

VKTX
VKTX Viking Therapeutics Inc
$28.44 -0.77%
View chart & analysis →
  1. 1UBS assigned a buy rating to Viking Therapeutics with a 12-month price target of $94.
  2. 2Viking's injectable treatment recorded an average weight loss of 14.7% after only 13 weeks in a Phase 2 clinical trial.
  3. 3Patients receiving weekly VK2735 showed weight loss of 16% to 19% after 21 weeks.

So what's the key point?

UBS expects Viking Therapeutics stock to rise and set a target of $94. Results showed patients lost 14.7% of their body weight after 13 weeks of treatment.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Eli Lilly widens market cap gap with Novo Nordisk in obesity treatment competition The Motley Fool +7 · 2d agoViking Therapeutics shares fall approximately 23% below capital increase issue price The Motley Fool +1 · Nov 4$10,000 Investment Strategy: Balancing Dividends and Growth Stocks The Motley Fool +1 · Nov 4
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news